Comparing desferrioxamine and light fractionation enhancement of ALA-PpIX photodynamic therapy in skin cancer

British Journal of Cancer

Volumn 115, Issue 7, 2016, Pages 805-813

  De Souza, Ana Luiza Ribeiro ^a,b   Marra, Kayla ^a   Gunn, Jason ^a   Samkoe, Kimberley S ^a,c   Kanick, Stephen Chad ^a   Davis, Scott C ^a   Chapman, M Shane ^c   Maytin, Edward V ^d   Hasan, Tayyaba ^e   Pogue, Brian W ^a,c  

^a DARTMOUTH COLLEGE   (United States)

^b MINISTRY OF EDUCATION OF BRAZIL   (Brazil)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

aminolevulinic acid; dose; fractionation; iron chelator; photodynamic; protoporphyrin IX

Indexed keywords

AMINOLEVULINIC ACID; DEFEROXAMINE; PHOTOSENSITIZING AGENT; PROTOPORPHYRIN; HEME; SIDEROPHORE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL OUTCOME; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DOSIMETRY; FEMALE; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; IRON CHELATION; LONG TERM SURVIVAL; MOUSE; NONHUMAN; OXYGEN SATURATION; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; SKIN CANCER; THERAPY EFFECT; TISSUE OXYGENATION; TREATMENT RESPONSE; TUMOR BLOOD FLOW; TUMOR VOLUME; WHITE LIGHT; ANIMAL; BIOSYNTHESIS; CARCINOMA, SQUAMOUS CELL; DEVICES; DIODE LASER; DRUG SCREENING; ILLUMINATION; NUDE MOUSE; PATHOLOGY; PHOTOCHEMOTHERAPY; PROCEDURES; RADIATION RESPONSE; RANDOMIZATION; SKIN NEOPLASMS; TUMOR CELL LINE;

AMINOLEVULINIC ACID; ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DEFEROXAMINE; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HEME; HUMANS; LASERS, SEMICONDUCTOR; LIGHTING; MICE; MICE, NUDE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PROTOPORPHYRINS; RANDOM ALLOCATION; SIDEROPHORES; SKIN NEOPLASMS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84984796615     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2016.267     Document Type: Article

References (50)

1. Allison RR, Sibata CH, Downie GH, Cuenca RE. (2006). A clinical review of PDT for cutaneous malignancies. Photodiagnosis Photodyn Ther 3: 214-226
2. Anand S, Honari G, Hasan T, Elson P, Maytin EV. (2009). Low-dose methotrexate enhances aminolevulinate-based photodynamic therapy in skin carcinoma cells in vitro and in vivo. Clin Cancer Res 15(10): 3333-3343
3. Araújo LMPC, Thomazine JA, Lopez RFV. (2010). Development of microemulsions to topically deliver 5-Aminolevulinic acid in photodynamic therapy. Eur J Pharm Biopharm 75: 48-55
4. Berg K, Anholt H, Bech O, Moan J. (1996). The influence of iron chelators on the accumulation of protoporphyrin IX in 5-Aminolaevulinic acid-Treated cells. Br J Cancer 74: 688-697
5. Blake E, Curnow A. (2010). The hydroxypyridinone iron chelator CP94 can enhance PpIX-induced PDT of cultured human glioma cells. Photochem Photobiol 86: 1154-1160
6. Bovis MJ, Woodhams JH, Loizidou M, Scheglmann D, Bown SG, MacRobert AJ. (2012). Improved in vivo delivery of m-THPC via pegylated liposomes for use in photodynamic therapy. J Control Release 157: 196-205
7. Braathen LR, Szeimies RM, Basset-Seguin N, Bissonnette R, Foley P, Pariser D, Roelandts R, Wennberg AM, Morton CA. (2007). Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. J Am Acad Dermatol 56: 125-143.
8. De Bruijn HS, Casas AG, Di Venosa G, Gandara L, Sterenborg HJ, Batlle A, Robinson DJ. (2013). Light fractionated ALA-PDT enhances therapeutic efficacy in vitro; the influence of PpIX concentration and illumination parameters. Photochem Photobiol Sci 12: 241-245
9. De Bruijn HS, Kruijt B, Van Der Ploeg-van den Heuvel A, Sterenborg HJ, Robinson DJ. (2007). Increase in protoporphyrin IX after 5-Aminolevulinic acid based photodynamic therapy is due to local re-synthesis. Photochem Photobiol Sci 6: 857-864
10. De Bruijn HS, Van Der Ploeg-van den Heuvel A, Sterenborg HJ, Robinson DJ. (2006). Fractionated illumination after topical application of 5-Aminolevulinic acid on normal skin of hairless mice: the influence of the dark interval. J Photochem Photobiol B 85: 184-190
11. Cairnduff F, Stringer MR, Hudson EJ, Ash DV, Brown SB. (1994). Superficial photodynamic therapy with topical 5-Aminolaevulinic acid for superficial primary and secondary skin cancer. Br J Cancer 69: 605-608
12. Campbell SM, Morton CA, Alyahya R, Horton S, Pye A, Curnow A. (2008). Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinoma. Br J Dermatol 159: 387-393
13. Celli JP, Spring BQ, Rizvi I, Evans CL, Samkoe KS, Verma S, Pogue BW, Hasan T. (2010). Imaging and photodynamic therapy: mechanisms, monitoring and optimization. Chem Rev 110: 2795-2838
14. Chang SC, MacRobert AJ, Porter JB, Bown SG. (1997). The efficacy of an iron chelator (CP94) in increasing cellular protoporphyrin IX following intravesical 5-Aminolaevulinic acid administration: an in vivo study. J Photochem Photobiol B 38: 114-122
15. Choudry K, Brooke RC, Farrar W, Rhodes LE. (2003). The effect of an iron chelating agent on protoporphyrin IX levels and phototoxicity in topical 5-Aminolaevulinic acid photodynamic therapy. Br J Dermatol 149: 124-130
16. Curnow A, Haller JC, Bown SG. (2000). Oxygen monitoring during 5-Aminolaevulinic acid induced photodynamic therapy in normal rat colon. Comparison of continuous and fractionated light regimes. J Photochem Photobiol B 58: 149-155
17. Curnow A, MacRobert AJ, Bown SG. (2006). Comparing and combining light dose fractionation and iron chelation to enhance experimental photodynamic therapy with aminolevulinic acid. Lasers Surg Med 38: 325-331
18. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, Moan J, Peng Q. (1998). Photodynamic therapy. J Natl Cancer Inst 90: 889-905
19. Fang YP, Tsai YH, Wu PC, Huang YB. (2008). Comparison of 5-Aminolevulinic acid-encapsulated liposome versus ethosome for skin delivery for photodynamic therapy. Int J Pharm 356: 144-152
20. Fingar VH, Wieman TJ, Wiehle SA, Cerrito PB. (1992). The role of microvascular damage in photodynamic therapy: the effect of treatment on vessel constriction, permeability, and leukocyte adhesion. Cancer Res 52: 4914-4921
21. Foster TH, Murant RS, Bryant RG, Knox RS, Gibson SL, Hilf R. (1991). Oxygen consumption and diffusion effects in photodynamic therapy. Radiat Res 126: 296-303
22. Gibbs SL, Chen B, O'Hara JA, Hoopes PJ, Hasan T, Pogue BW. (2006). Protoporphyrin IX level correlates with number of mitochondria, but increase in production correlates with tumor cell size. Photochem Photobiol 82: 1334-1341
23. De Haas ER, Kruijt B, Sterenborg HJ, Martino Neumann HA, Robinson DJ. (2006). Fractionated illumination significantly improves the response of superficial basal cell carcinoma to aminolevulinic acid photodynamic therapy. J Invest Dermatol 126: 2679-2686
24. De Haas ER, De Vijlder HC, Sterenborg HJ, Neumann HA, Robinson DJ. (2008). Fractionated aminolevulinic acid-photodynamic therapy provides additional evidence for the use of PDT for non-melanoma skin cancer. J Eur Acad Dermatol Venereol 22: 426-430
25. Hanania J, Malik Z. (1992). The effect of EDTA and serum on endogenous porphyrin accumulation and photodynamic sensitization of human K562 leukemic cells. Cancer Lett 65: 127-131
26. Henderson BW, Dougherty TJ. (1992). How does photodynamic therapy work?. Photochem Photobiol 55: 145-157
27. Henning JP, Fournier RL, Hampton JA. (1995). A transient mathematical model of oxygen depletion during photodynamic therapy. Radiat Res 142: 221-226
28. Ibbotson SH. (2010). An overview of topical photodynamic therapy in dermatology. Photodiagnosis Photodyn Ther 7: 16-23
29. Iinuma S, Farshi SS, Ortel B, Hasan T. (1994). A mechanistic study of cellular photodestruction with 5-Aminolaevulinic acid-induced porphyrin. Br J Cancer 70: 21-28
30. Iinuma S, Schomacker KT, Wagnieres G, Rajadhyaksha M, Bamberg M, Momma T, Hasan T. (1999). In vivo fluence rate and fractionation effects on tumor response and photobleaching: photodynamic therapy with two photosensitizers in an orthotopic rat tumor model. Cancer Res 59: 6164-6170
31. Kanick SC, Davis SC, Zhao Y, Sheehan KL, Hasan T, Maytin EV, Pogue BW, Chapman MS. (2015). Pre-Treatment protoporphyrin IX concentration in actinic keratosis lesions may be a predictive biomarker of response to aminolevulinic-Acid based photodynamic therapy. Photodiagnosis Photodyn Ther 12: 561-566
32. Kanick SC, Davis SC, Zhao Y, Hasan T, Maytin EV, Pogue BW, Chapman MS. (2014). Dual-channel red/blue fluorescence dosimetry with broadband reflectance spectroscopic correction measures protoporphyrin IX production during photodynamic therapy of actinic keratosis. J Biomed Opt 19: 75002
33. Kennedy JC, Pottier RH. (1992). Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J Photochem Photobiol B 14: 275-292
34. Kennedy JC, Pottier RH, Pross DC. (1990). Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol B 6: 143-148
35. Lee CC, Pogue BW, O'Hara JA, Wilmot CM, Strawbridge RR, Burke GC, Hoopes PJ. (2003). Spatial heterogeneity and temporal kinetics of photosensitizer (AlPcS2) concentration in murine tumors RIF-1 and MTG-B. Photochem Photobiol Sci 2: 145-150
36. Malik Z, Kostenich G, Roitman L, Ehrenberg B, Orenstein A. (1995). Topical application of 5-Aminolevulinic acid, DMSO and EDTA: protoporphyrin IX accumulation in skin and tumours of mice. J Photochem Photobiol B 28: 213-218
37. Maytin EV, Honari G, Khachemoune A, Taylor CR, Ortel B, Pogue BW, Sznycer-Taub N, Hasan T. (2012). Vitamin D combined with aminolevulinate (ALA)-mediated photodynamic therapy (PDT) for human psoriasis: a proof-of-principle study. Isr J Chem 52: 767-775
38. Middelburg TA, De Vijlder HC, De Bruijn HS, Van Der Ploeg-van den Heuvel A, Neumann HA, De Haas ER, Robinson DJ. (2014). Topical photodynamic therapy using different porphyrin precursors leads to differences in vascular photosensitization and vascular damage in normal mouse skin. Photochem Photobiol 90: 896-902
39. Morton CA, MacKie RM, Whitehurst C, Moore JV, McColl JH. (1998). Photodynamic therapy for basal cell carcinoma: effect of tumor thickness and duration of photosensitizer application on response. Arch Dermatol 134: 248-249
40. Palm MD, Goldman MP. (2011). Safety and efficacy comparison of blue versus red light sources for photodynamic therapy using methyl aminolevulinate in photodamaged skin. J Drugs Dermatol 10: 53-60
41. Peng Q, Warloe T, Moan J, Godal A, Apricena F, Giercksky KE, Nesland JM. (2001). Antitumor effect of 5-Aminolevulinic acid-mediated photodynamic therapy can be enhanced by the use of a low dose of photofrin in human tumor xenografts. Cancer Res 61: 5824-5832
42. Pye A, Curnow A. (2007). Direct comparison of delta-Aminolevulinic acid and methyl-Aminolevulinate-derived protoporphyrin IX accumulations potentiated by desferrioxamine or the novel hydroxypyridinone iron chelator CP94 in cultured human cells. Photochem Photobiol 83: 766-773
43. Redbord KP, Hanke CW. (2007). Topical photodynamic therapy for dermatologic disorders: results and complications. J Drugs Dermatol 6: 1197-1202
44. Robinson DJ, De Bruijn HS, Star WM, Sterenborg HJ. (2003). Dose and timing of the first light fraction in two-fold illumination schemes for topical ALA-mediated photodynamic therapy of hairless mouse skin. Photochem Photobiol 77: 319-323
45. Robinson DJ, De Bruijn HS, De Wolf WJ, Sterenborg HJ, Star WM. (2000). Topical 5-Aminolevulinic acid-photodynamic therapy of hairless mouse skin using two-fold illumination schemes: PpIX fluorescence kinetics, photobleaching and biological effect. Photochem Photobiol 72: 794-802
46. Rodriguez L, De Bruijn HS, Di Venosa G, Mamone L, Robinson DJ, Juarranz A, Batlle A, Casas A. (2009). Porphyrin synthesis from aminolevulinic acid esters in endothelial cells and its role in photodynamic therapy. J Photochem Photobiol B 96: 249-254
47. Star WM, van't Veen AJ, Robinson DJ, Munte K, De Haas ER, Sterenborg HJ. (2006). Topical 5-Aminolevulinic acid mediated photodynamic therapy of superficial basal cell carcinoma using two light fractions with a two-hour interval: long-Term follow-up. Acta Derm Venereol 86: 412-417
48. Uehlinger P, Zellweger M, Wagnieres G, Juillerat-Jeanneret L, Van den Bergh H, Lange N. (2000). 5-Aminolevulinic acid and its derivatives: physical chemical properties and protoporphyrin IX formation in cultured cells. J Photochem Photobiol B 54: 72-80
49. Valdes PA, Samkoe K, O'Hara JA, Roberts DW, Paulsen KD, Pogue BW. (2010). Deferoxamine iron chelation increases delta-Aminolevulinic acid induced protoporphyrin IX in xenograft glioma model. Photochem Photobiol 86: 471-475
50. Di Venosa G, Fukuda H, Batlle A, MacRobert A, Casas A. (2006). Photodynamic therapy: regulation of porphyrin synthesis and hydrolysis from ALA esters. J Photochem Photobiol B 83: 129-136